One of the best performers on the All Ordinaries index this year has been the Opthea Ltd (ASX: OPT) share price.
Since the start of the year the shares of the developer of novel biologic therapies for the treatment of eye diseases have rallied over 450% higher.
To put that into context, a $20,000 investment on January 1 would now be worth $110,000.
Why is the Opthea share price up 450% in 2019?
Investors have been buying Opthea’s shares in a hurry this year following the success of a study related to its OPT-302 combination therapy for treatment-naïve patients with wet age-related macular degeneration (AMD).
According to the study update, the OPT-302 (2.0 mg) combination therapy showed statistical superiority for the most accepted and sensitive primary efficacy outcome.
This has the potential to be a major positive for the company. This is because the current standard of care treatments for wet AMD had sales of US$3.7 billion in 2018.
Furthermore, there is potential for the therapy to be used for Diabetic Macular Edema (DME) as well. The current standard of care for DME generated sales of US$6.2 billion in 2018.
Combined, the OPT-302 combination therapy has a ~US$10 billion market opportunity. In light of this, I can’t say I’m surprised to see its shares race higher this year.
What else has driven its shares higher?
One broker that is especially bullish on the company is Goldman Sachs. Following the study update, the broker added Opthea to its conviction list with a buy rating and $4.90 price target.
This price target implies potential upside of over 40% for its shares, even after 2019’s stellar gains.
Goldman Sachs believes that “OPT-302 has multi-billion dollar potential.”
Its analysts said: “As successful as current treatments have been, they only inhibit up to two of the factors responsible for the disease (VEGF-A/B). Over half of patients do not achieve significant vision gains, and a quarter experience continued vision loss. OPT-302 is intended for use in combination with these treatments, blocking a further two factors (VEGF-C/D), hence targeting improved outcomes via a more complete blockade.”
In light of this, it has suggested that in the future it could achieve “non-risk-adjusted peak sales of US$5.0bn (US$2.0bn risk-adjusted), of which US$3.4bn relates to wAMD (US$1.7bn).”
I think Goldman makes some great points and Opthea could be well worth considering. Though, it is a high risk investment at this stage.
Our experts here at The Motley Fool Australia have just released a fantastic report, detailing 5 dirt cheap shares that you can buy in 2020.
One stock is an Australian internet darling with a rock solid reputation and an exciting new business line that promises years (or even decades) of growth… while trading at an ultra-low price…
Another is a diversified conglomerate trading over 40% off its high, all while offering a fully franked dividend yield over 3%...
Plus 3 more cheap bets that could position you to profit over the next 12 months!
See for yourself now. Simply click here or the link below to scoop up your FREE copy and discover all 5 shares. But you will want to hurry – this free report is available for a brief time only.
James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has recommended ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.